|
Friday 16 July |
|
|
Session 1: Prevention of Mother to Child HIV Transmission: Guidelines and Program Implementation |
|||
|
Invited lecture: What's new and Why in WHO revised PMTCT guidelines |
E. Abrams |
|
|
|
Invited lecture: Operational research on PMTCT - Lessons learned and gaps |
L. Guay |
|
|
|
Invited lecture: PMPCT challenges - In country implementation |
D. Mbori-Ngacha |
|
|
|
Safety of tenofovir use during pregnancy: Associations with low birth weight and early growth in HIV-exposed uninfected infants |
G. Siberry |
|
|
|
Monitoring birth defects among HIV positive, ART exposed pregnant women: 20 years of antiretroviral pregnancy registry data |
V. Vannappagari |
|
|
|
Post-exposure prophylaxis of breastfeeding infants with antiretroviral drugs to age 14 weeks: updated efficacy results of the PEPI-Malawi trial. |
T. Taha |
|
|
|
Post-18 month confirmatory HIV testing in HIV DNA PCR positive children: retrospective descriptive analysis from an operational setting in Lesotho |
A. Garcia-Prats |
|
|
Session 2: Treatment of Pediatric HIV Infection (1) |
|||
|
Invited lecture: What’s new in WHO Pediatric Treatment Guidelines |
L. Mofenson |
|
|
|
Invited lecture: Managing children with treatment failure |
J. Ananworanich |
|
|
|
The evolution of paediatric antiretroviral treatment guidelines: what's the impact on the ground? |
M. Penazzato |
|
|
Session 3: Treatment of Pediatric HIV Infection (2) |
|||
|
Early mortality and loss to follow up after start of antiretroviral treatment in Malawian HIV infected children remains high |
P. Moons |
N.A. |
|
|
Response to early antiretroviral treatment in HIV-infected infants: the experience of the European Pregnancy and Paediatric HIV Cohorts Collaboration |
C. Townsend |
|
|
|
Viral load predicts WHO Stage 3 and 4 events in HIV-infected children on HAART, independent of CD4 T-lymphocyte value |
G. Siberry |
|
|
|
Combination antiretroviral regimens and treatment switching strategies in HIV-infected antiretroviral naive children aged 1 month-18 years |
G. Tudor-Williams |
|
|
|
Usefulness of immunological failure to identify virological failure and guide switching in children on antiretroviral therapy |
B. Eley |
|
|
Session 4: Complications of HIV and Its Treatment |
|||
|
Invited lecture: Metabolic complications of HIV and its treatment in children |
A. Vigano |
|
|
|
Invited lecture: Neurocognitive complications of HIV and its treatment in children |
M. Boivin |
|
|
|
Comparison of cardiac manifestation in treatment naïve children to those on antiretroviral treatment attending a pediatric HIV clinic in Tanzania |
W. Schimana |
|
|
|
Metabolic abnormalities in a European cohort of HIV-infected children and adolescents |
N. Alam |
|
|
|
Severe adverse events in HIV-infected children in Asia after first-line HAART |
T. Bunupuradah |
|
|
|
Prevalence of low bone mineral density and longitudinal changes in bone mineral content in perinatally HIV-infected adolescents |
A. Schtscherbyna |
N.A. |
|
|
Regulatory T cells and chronic immune activation in HIV-1 infected children |
R. Freguja |
N.A. |
|
|
|
a Medical Education company
